Particle.news
Download on the App Store
9 ARTICLES
·
yesterday

All 55 U.S. Attorneys General Approve $7.4 Billion Purdue Pharma Settlement

A restructured Purdue Pharma will redirect $7.4 billion toward opioid treatment following the Sacklers' exit from U.S. opioid sales.

Bottles of prescription painkiller OxyContin made by Purdue Pharma LP sit on a shelf at a local pharmacy in Provo, Utah, U.S., April 25, 2017. REUTERS/George Frey/File Photo
Image
Image

Overview

  • Fifty state attorneys general plus officials from Washington D.C. and four territories agreed to the settlement announced Monday.
  • The $7.4 billion payment resolves thousands of lawsuits alleging that Purdue’s painkiller OxyContin fueled a nationwide opioid addiction crisis.
  • The Sackler family will contribute billions from their personal fortune to a national opioid abatement trust without seeking bankruptcy protection.
  • As part of the agreement, the Sacklers will relinquish ownership of Purdue Pharma and permanently cease all opioid sales in the United States.
  • Under the terms, Purdue Pharma will be converted into a public benefit company tasked with directing its profits toward opioid addiction treatment and prevention.